Jump Financial LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 16,513 shares of the biopharmaceutical company's stock, valued at approximately $417,000.
Other hedge funds also recently modified their holdings of the company. Values First Advisors Inc. boosted its stake in shares of Celldex Therapeutics by 20.0% in the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock valued at $733,000 after purchasing an additional 4,837 shares during the last quarter. Barclays PLC raised its position in shares of Celldex Therapeutics by 140.7% in the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after acquiring an additional 76,207 shares during the period. SG Americas Securities LLC raised its position in shares of Celldex Therapeutics by 24.4% in the 4th quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock valued at $639,000 after acquiring an additional 4,967 shares during the period. Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at approximately $2,867,000. Finally, Swiss National Bank raised its position in shares of Celldex Therapeutics by 1.2% in the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after acquiring an additional 1,400 shares during the period.
Celldex Therapeutics Stock Performance
NASDAQ CLDX traded down $0.10 on Wednesday, reaching $20.83. The company had a trading volume of 684,578 shares, compared to its average volume of 884,828. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -8.11 and a beta of 1.59. Celldex Therapeutics, Inc. has a 1-year low of $14.40 and a 1-year high of $47.00. The company's fifty day moving average is $19.11 and its 200-day moving average is $23.34.
Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $1.18 million during the quarter, compared to analyst estimates of $1.25 million. On average, research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price target on the stock. Cantor Fitzgerald reiterated an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday. They issued a "buy" rating and a $64.00 price target on the stock. Finally, The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $55.30.
Check Out Our Latest Report on Celldex Therapeutics
About Celldex Therapeutics
(
Free Report)
Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.
Featured Articles
Before you consider Celldex Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celldex Therapeutics wasn't on the list.
While Celldex Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
